Month: April 2023

It’s less nature and more about noshing when it comes to the adverse impact of obesity on the heart, a twin study from Sweden suggested. In an analysis of nearly all twins in the country, obesity predicted cardiovascular disease (CVD) risk across the board in every genetic risk group, reported Ida Karlsson, PhD, of the
0 Comments
This video is released at Mayo Clinic’s International Representative Office (IRO) launch event in Jakarta, Indonesia in 2023. It features three Indonesian patients and their experiences at Mayo. Ms. Wanandi had severe back pain for a long time and was diagnosed with spinal stenosis during a physical check-up at Mayo where she had a successful
0 Comments
US regulators may soon clear blood-based biomarker tests for colorectal cancer (CRC), expanding potential options for patients seeking more convenient forms of screening. Most recently, Guardant Health, Inc, announced the completion of its US premarket approval application for its Shield blood test to screen for CRC. Approval by the US Food and Drug Administration (FDA)
0 Comments
Why I Started Following a Low-Carbohydrate Diet After Almost a Decade With Diabetes – Diabetes Daily Learning Center Learning Center: LearningCenter Diabetes Daily does not provide medical advice,diagnosis or treatment.Get additional information.© 2005 – 2023 Everyday Health, Inc., a Ziff Davis company. Everyday Health is among the federally registered trademarks of Everyday Health, Inc. and
0 Comments
This April we have come together with partners to celebrate the inaugural Teenage and Young Adult Cancer Awareness month. We caught up with Caroline-May Huxley and Sandra Strauss to explore the importance of shedding a light on cancer in this age group and why, scientifically speaking, this is most certainly not a distinction without a
0 Comments
A University of California, Riverside, study has identified the biological underpinnings of a reproductive disorder caused by the mutation of a gene. This gene mutation also causes Fragile X Syndrome, a leading genetic cause of intellectual impairment and autism. The researchers found mutations of the Fragile X messenger ribonucleoprotein 1 gene, or FMR1, contribute to
0 Comments
Michael Regan, administrator of the Environmental Protection Agency (EPA), speaks during an event at the EPA headquarters in Washington, D.C., U.S., on Monday, Dec. 20, 2021. Samuel Corum | Bloomberg | Getty Images The Environmental Protection Agency on Wednesday said it will strengthen limits on several toxic air pollutants emitted by power plants, including mercury, a
0 Comments
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today
0 Comments
When the Biden administration killed the X waiver late last year, all clinicians registered with the Drug Enforcement Administration (DEA) learned they would need 8 hours of training on substance use disorder (SUD) management in order to renew their licenses. The DEA has now issued a deadline for that requirement, and it’s less than 3
0 Comments
The youngest patient with cannabis-induced psychosis (CIP) whom Karen Randall, DO, has treated was a 7-year-old boy. She remembers the screaming, the yelling, the uncontrollable rage. Randall is an emergency medicine physician at Southern Colorado Emergency Medicine Associates, a group practice in Pueblo, Colorado. She treats youth for cannabis-related medical problems in the emergency department
0 Comments
Isaac Kohane, founding chair of the Department of Biomedical Informatics (DBMI) in the Blavatnik Institute at Harvard Medical School, discusses efficacy testing of artificial intelligence widgets and his appointment as editor-in-chief of the inaugural New England Journal of Medicine AI. Connect with Dr. Kohane on social media and continue the conversation: Twitter: https://bit.ly/ZakKohaneTwitter LinkedIn: https://bit.ly/ZakKohaneLinkedin
0 Comments
Editor’s Note: Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. CNN  —  Alzheimer’s disease strikes women harder than men — over two-thirds of those who descend into dementia’s devastating twilight are female at birth. That’s
0 Comments
(Reuters) – A Delaware judge on Monday dismissed Merck & Co’s lawsuit seeking to hold Bayer AG responsible for more talc-related liabilities stemming from its $14.2 billion purchase of Merck’s consumer care business in 2014. Vice Chancellor Nathan Cook of the Delaware Chancery Court said the purchase agreement “clearly and unambiguously” left Merck liable for
0 Comments
LEIDEN, Netherlands, April 3, 2023. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced that the first patient has been dosed in a Phase 1/2a clinical study evaluating VO659 for the treatment of Huntington’s disease (HD), spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3). VO659 is an
0 Comments
In this article ILMN Follow your favorite stocksCREATE FREE ACCOUNT Francis deSouza, chief executive officer of Illumina Inc., during a panel session on day three of the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 19, 2023. Stefan Wermuth | Bloomberg | Getty Images The Federal Trade Commission on Monday ordered Illumina to
0 Comments
The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) as first-line treatment for certain patients with locally advanced or metastatic urothelial cancer, the agency announced on Monday. Specifically, the combination is indicated for those who are ineligible for cisplatin-containing chemotherapy, and the approval marks the first anti-PD-1/antibody-drug conjugate combination for this patient
0 Comments